...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy
【24h】

Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy

机译：接受抗逆转录病毒治疗的HIV感染儿童再次接种疫苗后3年的乙型肝炎抗体保护水平水平

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

After responding to highly active antiretroviral therapy (HAART), HIV-infected children had a good response to hepatitis B immunization. However, there are limited data on the durability of antibody to hepatitis B surface antigen (anti-HBs) in these children. The primary objective of this study is to determine the prevalence of protective anti-HBs level 3 years after a 3-dose HBV revaccination among HIV-infected children with immune recovery (CD4 cell >= 15%) while on HAART. The secondary objective is to assess immunologic memory among children who had waning of anti-HBs. An anti-HBs level of >= 10 mIU/mL was defined as a protective antibody level. Sixty-nine HIV-infected children who had history of a 3-dose HBV revaccination while receiving HAART were enrolled. The mean (SD) of CD4 cell and duration of HAART at time of revaccination was 27.2% (6.7) and 5.9 years (0.4), respectively. The proportion of children with protective anti-HBs level 3 years after the revaccination was 71.0% [95% CI, 58.8-81.3]. The geometric mean titer was 114(SD 5) IU/mL. By multivariate logistic analysis, the predictors for protective anti-HBs level 3 years after revaccination were CD4 cell count >= 500 cells/mm(3) at the time of vaccination (p = 0.04) and anti-HBs level >= 100 IU/mL at 1 month after completion of the 3-dose vaccination (p < 0.001). Anamnestic response after one booster dose was demonstrated among 14 of 17 children who had waning protective anti-HBs level (82.4% [95% CI, 62.2-102.6]). Our findings support the recommendation of giving a 3-dose HBV vaccination to HIV-infected children with immune recovery while receiving HAART
机译：在对高效抗逆转录病毒疗法（HAART）做出反应后，感染HIV的儿童对乙肝免疫接种反应良好。但是，在这些儿童中，针对乙型肝炎表面抗原（抗HBs）的抗体的持久性数据有限。这项研究的主要目的是确定3剂量的HBV疫苗接种3年后，在接受HAART的HIV感染儿童的免疫恢复（CD4细胞> = 15％）中，保护性抗HBs水平的患病率。次要目标是评估抗HBs减弱的儿童的免疫记忆。 ≥10 mIU / mL的抗HBs水平定义为保护性抗体水平。入选了接受HAART期间有3剂HBV疫苗再接种史的69名受HIV感染的儿童。再次接种时，CD4细胞的平均（SD）和HAART持续时间分别为27.2％（6.7）和5.9年（0.4）。免疫后3年，具有保护性抗HBs水平的儿童比例为71.0％[95％CI，58.8-81.3]。几何平均滴度为114（SD 5）IU / mL。通过多因素logistic分析，预防接种后3年抗HBs保护水平的预测指标是接种时CD4细胞计数> = 500细胞/ mm（3）（p = 0.04）和抗HBs水平> = 100 IU /在完成3剂疫苗接种后1个月的平均mL（p <0.001）。在17例保护性抗HBs水平下降的儿童中，有14例表现出加强剂量后的记忆消除（82.4％[95％CI，62.2-102.6]）。我们的发现支持以下建议：在接受HAART的同时对感染HIV的儿童进行3剂量的HBV疫苗接种

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号